NO20072665L - Rapamycinderivater og deres anvendelse i behandling av nevrologiske lidelser - Google Patents
Rapamycinderivater og deres anvendelse i behandling av nevrologiske lidelserInfo
- Publication number
- NO20072665L NO20072665L NO20072665A NO20072665A NO20072665L NO 20072665 L NO20072665 L NO 20072665L NO 20072665 A NO20072665 A NO 20072665A NO 20072665 A NO20072665 A NO 20072665A NO 20072665 L NO20072665 L NO 20072665L
- Authority
- NO
- Norway
- Prior art keywords
- neurological disorders
- treatment
- rapamycin derivatives
- compounds
- rapamycin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63800404P | 2004-12-20 | 2004-12-20 | |
PCT/US2005/045331 WO2006068905A2 (en) | 2004-12-20 | 2005-12-15 | Rapamycin derivatives and the uses thereof in the treatment of neurological disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20072665L true NO20072665L (no) | 2007-09-07 |
Family
ID=36602218
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20072665A NO20072665L (no) | 2004-12-20 | 2007-05-25 | Rapamycinderivater og deres anvendelse i behandling av nevrologiske lidelser |
Country Status (16)
Country | Link |
---|---|
US (3) | US7273874B2 (zh) |
EP (1) | EP1828203A2 (zh) |
JP (1) | JP2008524232A (zh) |
KR (1) | KR20070090931A (zh) |
CN (1) | CN101084226A (zh) |
AU (1) | AU2005319427B2 (zh) |
BR (1) | BRPI0519593A2 (zh) |
CA (1) | CA2590254A1 (zh) |
CR (1) | CR9149A (zh) |
IL (1) | IL183772A0 (zh) |
MX (1) | MX2007007409A (zh) |
NI (1) | NI200700156A (zh) |
NO (1) | NO20072665L (zh) |
RU (1) | RU2007119585A (zh) |
WO (1) | WO2006068905A2 (zh) |
ZA (1) | ZA200705123B (zh) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100402031C (zh) | 2002-07-30 | 2008-07-16 | 惠氏公司 | 含有瑞帕霉素羟基酯的胃肠外制剂 |
WO2005085257A1 (en) * | 2004-03-02 | 2005-09-15 | Wyeth | Macrolides and methods for producing same |
WO2005121327A2 (en) * | 2004-06-03 | 2005-12-22 | Wyeth | Biosynthetic gene cluster for the production of a complex polyketide |
RU2394036C2 (ru) * | 2004-12-20 | 2010-07-10 | Вайет | Аналоги рапамицина и их применение при лечении неврологических, пролиферативных и воспалительных заболеваний |
MX2007007409A (es) * | 2004-12-20 | 2007-07-12 | Wyeth Corp | Derivados de rapamicina y los usos de los mismos en el tratamiento de trastornos neurologicos. |
WO2006096529A2 (en) * | 2005-03-07 | 2006-09-14 | Novartis Ag | Genes involved in neurodegenerative conditions |
EP1957500A1 (en) * | 2005-12-07 | 2008-08-20 | Wyeth a Corporation of the State of Delaware | Process for the preparation of purified crystalline cci-779 |
US7622578B2 (en) * | 2005-12-07 | 2009-11-24 | Wyeth | Scalable process for the preparation of a rapamycin 42-ester from a rapamycin 42-ester boronate |
AR058283A1 (es) * | 2005-12-07 | 2008-01-30 | Wyeth Corp | Metodos para la preparacion de rapamicina cristalina y para la medicion de la cristalinidad de los compuestos de rapamicina utilizando calorimetria diferencial de barrido |
EP1991551A1 (en) | 2006-03-07 | 2008-11-19 | Wyeth a Corporation of the State of Delaware | Meridamycin analogues for the treatment of neurodegenerative disorders |
TW200824713A (en) * | 2006-10-18 | 2008-06-16 | Wyeth Corp | Processes for the synthesis of individual isomers of mono-PEG CCI-779 |
US8414910B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US20080175887A1 (en) | 2006-11-20 | 2008-07-24 | Lixiao Wang | Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs |
US9700704B2 (en) | 2006-11-20 | 2017-07-11 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US8414525B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US20080276935A1 (en) | 2006-11-20 | 2008-11-13 | Lixiao Wang | Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
US8998846B2 (en) | 2006-11-20 | 2015-04-07 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US8414526B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids |
US8425459B2 (en) | 2006-11-20 | 2013-04-23 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent |
US9737640B2 (en) | 2006-11-20 | 2017-08-22 | Lutonix, Inc. | Drug releasing coatings for medical devices |
CA2676613A1 (en) * | 2007-01-29 | 2008-08-07 | Wyeth | Immunophilin ligands and methods for modulating immunophilin and calcium channel activity |
JP2008305262A (ja) * | 2007-06-08 | 2008-12-18 | Konica Minolta Business Technologies Inc | サーバ及びシンクライアント環境でのプリンタ紹介方法 |
AU2008307643B9 (en) | 2007-09-28 | 2014-04-17 | Intrexon Corporation | Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof |
US20090209527A1 (en) * | 2008-02-19 | 2009-08-20 | Wyeth | Methods for Using Rapamycin Analogues in the Treatment of Neurological Disorders |
WO2010024898A2 (en) | 2008-08-29 | 2010-03-04 | Lutonix, Inc. | Methods and apparatuses for coating balloon catheters |
US20120064143A1 (en) | 2008-11-11 | 2012-03-15 | The Board Of Regents Of The University Of Texas System | Inhibition of mammalian target of rapamycin |
DE102008060549A1 (de) | 2008-12-04 | 2010-06-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung |
US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
MX362513B (es) | 2010-03-23 | 2019-01-22 | Intrexon Corp | Vectores que expresan de manera condicional proteinas terapeuticas, celulas hospedadoras que comprenden vectores, y usos de los mismos. |
ES2372077B2 (es) * | 2010-06-24 | 2012-05-18 | Universidad De Sevilla | Uso de la rapamicina para el tratamiento de los déficits cognitivos asociados al s�?ndrome de down. |
JP6189754B2 (ja) | 2011-03-04 | 2017-08-30 | イントレキソン コーポレーション | タンパク質を条件的に発現するベクター |
CN102274219A (zh) * | 2011-06-27 | 2011-12-14 | 苏州大学附属第一医院 | 雷帕霉素在治疗蛛网膜下腔出血早期脑损伤的应用 |
EP2906214A1 (en) | 2012-10-12 | 2015-08-19 | The Board of Regents of The University of Texas System | Use of mtor inhibitors to treat vascular cognitive impairment |
US9121859B2 (en) * | 2012-12-04 | 2015-09-01 | Siemens Healthcare Diagnostics Inc. | Compounds and methods for determination of FKBP-binding immunosuppressant drugs |
WO2014160328A1 (en) | 2013-03-13 | 2014-10-02 | The Board Of Regents Of The University Of Texas System | Mtor inhibitors for prevention of intestinal polyp growth |
US9700544B2 (en) | 2013-12-31 | 2017-07-11 | Neal K Vail | Oral rapamycin nanoparticle preparations |
AU2014373683B2 (en) | 2013-12-31 | 2020-05-07 | Rapamycin Holdings, Llc | Oral rapamycin nanoparticle preparations and use |
UY37343A (es) | 2016-07-25 | 2018-02-28 | Intrexon Corp | Control del fenotipo en plantas |
MX2019005235A (es) | 2016-11-09 | 2019-12-05 | Intrexon Corp | Constructos de expresion de frataxina. |
ES2871499T3 (es) | 2017-05-15 | 2021-10-29 | Bard Inc C R | Dispositivo médico con recubrimiento de elución de fármaco y capa intermedia |
WO2019157374A1 (en) * | 2018-02-09 | 2019-08-15 | Mount Tam Therapeutics, Inc. | Rapamycin analog for prevention and/or treatment of neurodegenerative conditions |
WO2019157382A1 (en) * | 2018-02-09 | 2019-08-15 | Mount Tam Therapeutics, Inc. | Rapamycin analog for prevention and/or treatment of neurodegenerative conditions |
EP3880266A1 (en) | 2018-11-14 | 2021-09-22 | Lutonix, Inc. | Medical device with drug-eluting coating on modified device surface |
US20220176084A1 (en) | 2019-04-08 | 2022-06-09 | Bard Peripheral Vascular, Inc. | Medical device with drug-eluting coating on modified device surface |
WO2022033529A1 (zh) * | 2020-08-12 | 2022-02-17 | 洪明奇 | Sema3d拮抗剂在预防或治疗神经退行性疾病以及延长寿命中的用途 |
US20230108125A1 (en) * | 2021-06-25 | 2023-04-06 | Apertor Pharmaceuticals, Inc. | Small molecule compounds |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1445742A1 (de) | 1963-11-06 | 1968-12-19 | Bayer Ag | Verfahren zur Herstellung von 2-Stellung substituierten Benzoxazinonen |
DE1545824A1 (de) | 1965-06-21 | 1969-12-11 | Bayer Ag | Verfahren zur Herstellung von 2-Sulfonamido- bzw. 2-Sulfonhydrazido-Benzoxazinonen |
GB1325047A (en) | 1969-08-11 | 1973-08-01 | Ciba Geigy Ag | Rifamycin compounds and processes for their manufacture |
US3686238A (en) | 1970-01-19 | 1972-08-22 | Syntex Corp | Glycerol esterified with 2-naphthyl-acetic acids and fatty acids |
US3900465A (en) | 1973-04-05 | 1975-08-19 | Lepetit Spa | 3-formylrifamycin azines |
US3905981A (en) | 1973-10-12 | 1975-09-16 | Research Corp | N-dealkylation of tertiary amines |
US4127720A (en) | 1977-09-21 | 1978-11-28 | Bristol-Myers Company | Pyrimido[2,1-a]isoquinoline derivatives having antiallergy activity |
JPH0262875A (ja) | 1988-05-23 | 1990-03-02 | Wakunaga Pharmaceut Co Ltd | 新規イソインドリン誘導体 |
EP0533930A1 (en) | 1990-06-11 | 1993-03-31 | Fujisawa Pharmaceutical Co., Ltd. | Use of a macrolide compound such as fk 506 for manufacturing a medicament for treating idiopathic thrombocytopenic purpura and basedow's disease |
DE4021404A1 (de) | 1990-07-05 | 1992-01-09 | Sandoz Ag | Heteroatome enthaltende trycyclische verbindungen, verfahren zu ihrer herstellung und ihre verwendung |
US5023262A (en) | 1990-08-14 | 1991-06-11 | American Home Products Corporation | Hydrogenated rapamycin derivatives |
GB2249027A (en) | 1990-10-23 | 1992-04-29 | Fujisawa Pharmaceutical Co | Use of macrolide compounds for hepatic failure |
WO1992013862A1 (en) | 1991-02-05 | 1992-08-20 | Fujisawa Pharmaceutical Co., Ltd. | Lactone compounds |
KR100351222B1 (ko) | 1991-09-05 | 2002-09-05 | 아보트 러보러터리즈 | 매크로사이클릭 면역 조절제 및 이의 제조방법 |
US5604294A (en) | 1991-09-05 | 1997-02-18 | Luly; Jay R. | Macrocyclic immunomodulators |
ZA935112B (en) | 1992-07-17 | 1994-02-08 | Smithkline Beecham Corp | Rapamycin derivatives |
ZA935111B (en) | 1992-07-17 | 1994-02-04 | Smithkline Beecham Corp | Rapamycin derivatives |
WO1994025022A1 (en) | 1993-04-23 | 1994-11-10 | Abbott Laboratories | Rapamycin conjugates and antibodies |
US7279561B1 (en) | 1993-04-23 | 2007-10-09 | Wyeth | Anti-rapamycin monoclonal antibodies |
US5798355A (en) | 1995-06-07 | 1998-08-25 | Gpi Nil Holdings, Inc. | Inhibitors of rotamase enzyme activity |
US5525610A (en) | 1994-03-31 | 1996-06-11 | American Home Products Corporation | 42-Epi-rapamycin and pharmaceutical compositions thereof |
US5696135A (en) | 1995-06-07 | 1997-12-09 | Gpi Nil Holdings, Inc. | Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth |
TW427904B (en) | 1995-12-07 | 2001-04-01 | American Home Prod | Neuroprotective agents |
US5717092A (en) | 1996-03-29 | 1998-02-10 | Vertex Pharmaceuticals Inc. | Compounds with improved multi-drug resistance activity |
US5780484A (en) | 1996-11-13 | 1998-07-14 | Vertex Pharmaceuticals Incorporated | Methods for stimulating neurite growth with piperidine compounds |
US6187784B1 (en) | 1998-06-03 | 2001-02-13 | Gpi Nil Holdings, Inc. | Pipecolic acid derivative hair growth compositions and uses |
JP2002516839A (ja) | 1998-06-03 | 2002-06-11 | ジーピーアイ エヌアイエル ホールディングス, インコーポレイテッド | ピペコリン酸誘導体毛髪成長組成物およびその使用 |
US6376517B1 (en) | 1998-08-14 | 2002-04-23 | Gpi Nil Holdings, Inc. | Pipecolic acid derivatives for vision and memory disorders |
US6015809A (en) | 1998-08-17 | 2000-01-18 | American Home Products Corporation | Photocyclized rapamycin |
CA2340700A1 (en) | 1998-08-17 | 2000-02-24 | American Home Products Corporation | Photocyclized rapamycins |
AU2478500A (en) | 1998-12-08 | 2000-06-26 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
US6441017B1 (en) | 1999-09-09 | 2002-08-27 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
US6569867B2 (en) | 1999-10-01 | 2003-05-27 | Kosan Biosciences, Inc. | Polyketide derivatives |
ES2283344T3 (es) | 1999-10-29 | 2007-11-01 | Kosan Biosciences, Inc. | Analogos de la rapamicina. |
WO2001087884A2 (en) | 2000-05-17 | 2001-11-22 | Kosan Biosciences, Inc. | Polyketide derivatives |
WO2003018573A1 (en) | 2001-08-22 | 2003-03-06 | Wyeth | Rapamycin 29-enols |
US6680330B2 (en) | 2001-08-22 | 2004-01-20 | Wyeth | Rapamycin dialdehydes |
US7300942B2 (en) | 2002-07-16 | 2007-11-27 | Biotica Technology Limited | Production of polyketides and other natural products |
MX2007007409A (es) * | 2004-12-20 | 2007-07-12 | Wyeth Corp | Derivados de rapamicina y los usos de los mismos en el tratamiento de trastornos neurologicos. |
RU2394036C2 (ru) * | 2004-12-20 | 2010-07-10 | Вайет | Аналоги рапамицина и их применение при лечении неврологических, пролиферативных и воспалительных заболеваний |
EP1991551A1 (en) * | 2006-03-07 | 2008-11-19 | Wyeth a Corporation of the State of Delaware | Meridamycin analogues for the treatment of neurodegenerative disorders |
-
2005
- 2005-12-15 MX MX2007007409A patent/MX2007007409A/es active IP Right Grant
- 2005-12-15 CA CA002590254A patent/CA2590254A1/en not_active Abandoned
- 2005-12-15 KR KR1020077013852A patent/KR20070090931A/ko not_active Application Discontinuation
- 2005-12-15 RU RU2007119585/04A patent/RU2007119585A/ru not_active Application Discontinuation
- 2005-12-15 WO PCT/US2005/045331 patent/WO2006068905A2/en active Application Filing
- 2005-12-15 EP EP05854115A patent/EP1828203A2/en not_active Withdrawn
- 2005-12-15 US US11/300,941 patent/US7273874B2/en not_active Expired - Fee Related
- 2005-12-15 AU AU2005319427A patent/AU2005319427B2/en not_active Ceased
- 2005-12-15 BR BRPI0519593-4A patent/BRPI0519593A2/pt not_active IP Right Cessation
- 2005-12-15 JP JP2007546876A patent/JP2008524232A/ja active Pending
- 2005-12-15 CN CNA2005800437050A patent/CN101084226A/zh active Pending
-
2007
- 2007-05-24 CR CR9149A patent/CR9149A/es not_active Application Discontinuation
- 2007-05-25 NO NO20072665A patent/NO20072665L/no not_active Application Discontinuation
- 2007-06-07 IL IL183772A patent/IL183772A0/en unknown
- 2007-06-18 NI NI200700156A patent/NI200700156A/es unknown
- 2007-06-19 ZA ZA200705123A patent/ZA200705123B/xx unknown
- 2007-08-14 US US11/891,879 patent/US7476678B2/en not_active Expired - Fee Related
-
2008
- 2008-12-05 US US12/329,106 patent/US20090088448A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CR9149A (es) | 2007-10-23 |
KR20070090931A (ko) | 2007-09-06 |
IL183772A0 (en) | 2007-09-20 |
US7476678B2 (en) | 2009-01-13 |
CA2590254A1 (en) | 2006-06-29 |
RU2007119585A (ru) | 2009-01-27 |
US20060135550A1 (en) | 2006-06-22 |
US20090088448A1 (en) | 2009-04-02 |
AU2005319427A1 (en) | 2006-06-29 |
AU2005319427B2 (en) | 2011-11-03 |
JP2008524232A (ja) | 2008-07-10 |
MX2007007409A (es) | 2007-07-12 |
BRPI0519593A2 (pt) | 2009-02-25 |
US20080027089A1 (en) | 2008-01-31 |
WO2006068905A3 (en) | 2006-12-07 |
NI200700156A (es) | 2008-06-17 |
CN101084226A (zh) | 2007-12-05 |
US7273874B2 (en) | 2007-09-25 |
EP1828203A2 (en) | 2007-09-05 |
WO2006068905A2 (en) | 2006-06-29 |
ZA200705123B (en) | 2010-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20072665L (no) | Rapamycinderivater og deres anvendelse i behandling av nevrologiske lidelser | |
EA200870093A1 (ru) | Применение производных бензоконденсированного гетероциклического сульфамида для лечения ожирения | |
NO20072664L (no) | Rapamycinanaloger og anvendelser derav for behandling av neurologiske, proliferative og inflamatoriske forstyrrelser | |
DK1543011T3 (da) | Thienopyrrolyl- og furanopyrrolylforbindelser og deres anvendelse som histamin H4-receptorligander | |
EA200800081A1 (ru) | Бензамидные производные (варианты), содержащая их фармацевтическая композиция (варианты), способ лечения заболеваний, связанных с модуляцией гидроксистероиддегидрогеназ на основе указанных производных(варианты) | |
NO20081315L (no) | Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser | |
NO20064929L (no) | Sulfonamid-tiazolpyrldinderivater som glukokinaseaktivatorer anvendelige i behandlingen av type 2 diabetes | |
ZA200703002B (en) | Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity | |
NO20080475L (no) | Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators | |
BRPI0506970A (pt) | derivados de alfa-aminoamida úteis no tratamento de distúrbios do trato urinário inferior | |
NO20074959L (no) | Substituerte pyridinderivater | |
NO20082096L (no) | Azaindol-2-karboksamidderivativer | |
WO2005086656A3 (en) | Heteroarylaminopyrazole derivatives useful for the treatment of diabetes | |
WO2006110187A3 (en) | Methods and compositions for the treatment of anxiety disorders | |
NO20082136L (no) | 1,5-substituerte indol-2-yl-amidderivater | |
WO2007145835A3 (en) | Benzamide derivatives as modulators of 11beta-hsd1 for treating diabetes and obesity | |
WO2008115999A8 (en) | Biaryl and biheteroaryl compounds useful in treating iron disorders | |
NO20083036L (no) | Anvendelse av benzofuserte heterocykliske sulfamidderivater for behandling av depresjon | |
NO20083058L (no) | Cykloheksylsulfonamidderivater med H3 reseptor aktivitet | |
EP1814535A4 (en) | NITROSED AND NITROSYLATED COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING EYE DISEASES | |
DK1926729T3 (da) | Benzothiazolcyclobutylaminderivater og deres anvendelse som histamin-3-receptorligander | |
BR0316723A (pt) | Derivados de anilinopirazol úteis para o tratamento de diabetes | |
EA200600071A1 (ru) | Производные n-фенилпиперазина и способы профилактики или лечения заболеваний, связанных с 5ht-рецептором | |
NO20082214L (no) | 1,1-Diokso-tiomorfolinyl-indolyl-metanonderivater for anvendelse som H3-modulatorer | |
WO2002079169A8 (en) | Cyano-substituted dihydropyrimidine compounds and their use to treat diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |